Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 11 07 2018
revised: 30 09 2018
accepted: 23 10 2018
pubmed: 24 11 2018
medline: 19 5 2020
entrez: 24 11 2018
Statut: ppublish

Résumé

Coronary artery perforation (CAP) is a rare but severe complication during percutaneous coronary intervention (PCI). Implantation of covered stents (CS) represents a potentially life-saving treatment. Concerns exist regarding limited efficacy and high stent thrombosis (ST) rates related to early generation CS. The aim of this study was to evaluate angiographic and clinical outcomes of patients with CAP treated with a new generation single-layer polytetrafluoroethylene (PTFE)-CS. Between May 2013 and November 2017, we identified a total of 61 patients who underwent implantation of 71 single layer PTFE-CS after CAP. We analyzed angiographic results at follow up (including binary angiographic restenosis [BAR] and late-lumen-loss [LLL]) and clinical outcomes in hospital and at follow up, including target lesion revascularization (TLR), cardiovascular-, and all-cause mortality, myocardial infarction (MI) and stent thrombosis (ST). Procedural success was achieved in all but two patients (96.7%). Procedure related MI, occurred in 19 cases (31.1%), in hospital death occurred in five cases (8.2%). At follow-up, TLR occurred in 11 cases (18.0%), two patients (3.3%) died from non-cardiovascular cause, there was no case of MI or ST. In this retrospective analysis, implantation of a new generation PTFE-CS, for the treatment of CAP showed high technical success rates. Although, periprocedural MI-and in-hospital-death rates remain not inconsiderable, new generation PTFE-CS showed favorable angiographic and clinical efficacy and high safety profile, especially with regard to thrombotic events.

Identifiants

pubmed: 30467994
doi: 10.1002/ccd.27979
doi:

Substances chimiques

Coated Materials, Biocompatible 0
Polytetrafluoroethylene 9002-84-0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

912-920

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Sebastian Kufner (S)

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.

Nora Schacher (N)

Department of Internal Medicine 2, University of Erlangen, Erlangen, Germany.

Miroslaw Ferenc (M)

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.

Christian Schlundt (C)

Department of Internal Medicine 2, University of Erlangen, Erlangen, Germany.

Petra Hoppmann (P)

I. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Mohamed Abdel-Wahab (M)

Herzzentrum der Segeberger Kliniken GmbH, Bad Segeberg, Germany.

Katharina Mayer (K)

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.

Massimiliano Fusaro (M)

Universitätsherzzentrum Bad Krotzingen, Kardiologie 1, Bad Krotzingen, Germany.

Robert A Byrne (RA)

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Adnan Kastrati (A)

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH